US FDA to hear from opioid sponsors on status of classwide REMS
18 November 2009
Sue Sutter
The US
FDA will hold a public meeting with sponsors of long-acting opioids on December 4th to discuss their progress in developing a single risk evaluation and mitigation strategy (REMS) for the class.
The meeting will be the second public forum on development of a class-wide REMS for long-acting...
Please Login to read the full article.
18 November 2009
Sue Sutter
The meeting will be the second public forum on development of a class-wide REMS for long-acting...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA orders opioid makers to develop doctor education programs
- US Capitol Capsule: Use of mind-altering medicines in children, elderly under fire
- European industry bodies voice concern over CoE's anti-counterfeiting system
- US Capitol Capsule: Supreme Court takes another stab at refining US patent law
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
